乌斯特基努马布治疗慢性口腔炎的有效性和安全性:一个前性的开放标签多中心研究
An Outtier1, Edouard Louis2, Olivier Dewit3
1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium; Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
概括
乌斯特基努马布在治疗慢性囊,性结肠炎手术的并发症方面表现出有效性. 这种生物疗法为患有这种疾病的患者提供了一种新的治疗选择.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠道疾病是什么
- 临床治疗学 临床治疗学
背景情况:
- 慢性囊炎影响了17%的患者后的proctocolectomy囊手术性结肠炎.
- 确定慢性囊炎的有效治疗方法对于改善患者的治疗结果至关重要.
研究的目的:
- 评估乌斯特基努马布在患有慢性囊炎的患者中的疗效.
- 评估16周和48周的无类固醇缓解和反应率.
主要方法:
- 这是一项前性研究,招募了22名患有慢性口腔炎的患者.
- 在48周内静脉和皮下注射乌斯特基努马布.
- 基线,第16周和第48周对修改型普炎疾病活动指数 (mPDAI) 的评估.
主要成果:
- 27.3%的患者在第16周实现了无类固醇缓解,在第48周达到缓解的比例为36.4%.
- 54.5%的患者在第16周和第48周均取得了临床反应.
- 到第48周,mPDAI中位数 (整体,临床和内镜) 的显著降低.
结论:
- 乌斯特基努马布在约一半患有慢性口腔炎的患者中显示出有效性.
- 在慢性囊炎的治疗算法中,应考虑使用乌斯特基努马布.
- 临床试验.gov 标识符:NCT04089345.gov 临床试验.gov 临床试验.gov 临床试验.gov 临床试验.gov 临床试验.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
113
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
113
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Chronic Bowel Disorders: Introduction
445
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
445
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Peptic Ulcer Disease I: Introduction
164
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
164


